| First Author | Lin SZ | Year | 2025 |
| Journal | JHEP Rep | Volume | 7 |
| Issue | 8 | Pages | 101418 |
| PubMed ID | 40677688 | Mgi Jnum | J:380657 |
| Mgi Id | MGI:8279206 | Doi | 10.1016/j.jhepr.2025.101418 |
| Citation | Lin SZ, et al. (2025) C/EBPbeta-VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD. JHEP Rep 7(8):101418 |
| abstractText | BACKGROUND & AIMS: Kupffer cells (KCs) can promote hepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying molecular mechanisms are not fully understood. C/EBPbeta in macrophages can mediate metabolic and immune dysregulations. Therefore, we aimed to explore its role in KCs in MASLD pathogenesis. METHODS: A 12-week high-fat and high-cholesterol diet (HFHCD) model was used in wild-type or KC-specific Cebpb heterozygous knockout mice (n = 10 per group), followed by liver evaluation using histopathology, flow cytometry, and RNA-seq. RNA-seq of liver tissue (n = 3 per group) and C/EBPbeta CUT&Tag-seq of sorted KCs were comprehensively analyzed to elucidate the transcriptional regulatory network. Flow cytometry and immunofluorescence were used to detect the expression or distribution of key proteins. RESULTS: HFHCD induced prominent immune cell infiltration and a concomitant increase in C/EBPbeta in KCs. KC-specific Cebpb heterozygous knockout significantly reduced HFHCD-induced lobular inflammation (p <0.05) and inflammation-related gene expression (p <0.05) in the liver. Multi-omics analysis revealed increased C/EBPbeta activity in KCs in MASLD, leading to a selective promotive effect on MASLD-induced genes. Further integrated analysis identified Vcam1 as a key direct downstream gene of C/EBPbeta in KCs in MASLD, which involves C/EBPbeta-mediated activation of the Vcam1 promoter. VCAM1 was predominantly expressed in KCs in the hepatic tissue of MASLD mice and patients. KC-expressed VCAM1 was significantly increased in MASLD compared with healthy controls (p <0.01), and it promoted immune cell infiltration into the liver. CONCLUSIONS: Increased C/EBPbeta in KCs promotes pathogenic transcriptional activation, leading to increased VCAM1 expression and inflammatory cell infiltration in MASLD. Inhibition of C/EBPbeta in KCs might be a potential therapeutic strategy against hepatic inflammation in MASLD. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, but its pathogenesis remains elusive. In this study, we investigated the critical role of CCAAT/enhancer binding protein beta (C/EBPbeta) in Kupffer cells and its implications in MASLD pathogenesis. We found that an increased C/EBPbeta level in Kupffer cells promotes hepatic inflammation in MASLD by upregulating VCAM1 expression. Our findings provide valuable insights into the molecular mechanisms driving MASLD and propose a potential novel therapeutic target to mitigate hepatic inflammation in MASLD. |
